C-BAMWViCardia Therapeutics
mitochondrial dysfunction, AMPK activation, infusion therapy
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-BAMW
C-BAMWC-BAMWmitochondrial dysfunction, AMPK activation, infusion therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ViCardia Therapeutics mitochondrial dysfunction, AMPK activation, infusion therapy
ViCardia Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for heart failure and disorders involving mitochondrial dysfunction. Its lead program, GP531, is described as a potent infusion therapy entering Phase 2 for acute decompensated heart failure. GP531 acts as an AMP-activated protein kinase agonist intended to improve myocardial bioenergetics, ATP generation, and left ventricular ejection fraction.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
ViCardia Therapeutics — Translational · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 modality breadth (2 modalities…
Source: Deterministic